Vical Incorporated Presents Positive Correlation Between Response and Survival at American Society of Clinical Oncology for Completed Allovectin(R) Melanoma Trials

CHICAGO, June 6, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced results from new statistical analyses of data from three previously completed clinical trials of the company's Allovectin® immunotherapy in patients with metastatic melanoma, showing with strong positive correlation that responders lived significantly longer than nonresponders. In a Phase 2 study of high-dose (2 mg) Allovectin® in 127 chemo-refractory or chemo-intolerant patients with metastatic melanoma, the overall survival was 65% at one year, 43% at two years, and 32% at three years. The median overall survival was 18.8 months (95% CI: 14.8 – 26.2 months). Survival among the 15 clinical responders ranged from 18 months to more than seven years (median survival not reached; 95% CI: 35.5 months – not reached). The median overall survival for nonresponders in the Phase 2 study was 16.2 months (95% CI: 13.3 – 21.2 months), which is notably longer than historical survival for other metastatic melanoma treatments, suggesting that these patients also may have derived clinical benefit from Allovectin®.